A phase 1 study of miroliverELAP for the treatment of acute liver failure is currently underway; 1 first patient in the study underwent the procedure at Intermountain Medical Center in Murray, Utah Approximately 30% of acute liver failure (ALF) patients die without access to a liver transplant. 2 EDEN PRAIRIE, Minn. & MURRAY, Utah / Jun 24, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public... Read More